Biblio

Author Title [ Type(Desc)] Year
Filters: Author is Wagner-Johnston, Nina  [Clear All Filters]
Journal Article
Sterling CH, Tsai H-L, Holdhoff M, Bolaños-Meade J, Luznik L, Fuchs EJ, Huff CAnn, Gocke CB, Ali SAbbas, Borrello IM, et al. "Allogeneic blood or marrow transplant with non-myeloablative conditioning and high dose cyclophosphamide-based graft-versus-host disease prophylaxis for secondary central nervous system lymphoma". Transplant Cell Ther. 2021.
DeZern AE, Zahurak ML, Symons HJ, Cooke KR, Rosner GL, Gladstone DE, Huff CAnn, Swinnen LJ, Imus P, Borrello I, et al. Haploidentical BMT for severe aplastic anemia with intensive GVHD prophylaxis including posttransplant cyclophosphamide. Blood Adv. 2020;4(8):1770-1779.
Sehgal A, Hoda D, Riedell PA, Ghosh N, Hamadani M, Hildebrandt GC, Godwin JE, Reagan PM, Wagner-Johnston N, Essell J, et al. Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study. Lancet Oncol. 2022.
Schuster SJ, Tam CS, Borchmann P, Worel N, McGuirk JP, Holte H, Waller EK, Jaglowski S, Bishop MR, Damon LE, et al. Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol. 2021.
Rappazzo KC, Zahurak M, Bettinotti M, Ali SAbbas, Ambinder AJ, Bolaños-Meade J, Borrello I, DeZern AE, Gladstone D, Gocke C, et al. Nonmyeloablative, HLA-mismatched unrelated peripheral blood transplantation with high-dose posttransplantation cyclophosphamide. Transplant Cell Ther. 2021.
Shea L, Watkins MP, Wan F, Cashen A, Wagner-Johnston N, Jacoby M, Abboud C, DiPersio J, Hurd D, Jaglowski S, et al. A pilot study of lenalidomide maintenance therapy after autologous transplantation in relapsed or refractory classical Hodgkin lymphoma. Biol Blood Marrow Transplant. 2020.